I like Mbrk - Q1 came out yesterday - burn was much less in Q1 than I expected. These guys blew it overestimating the penetration that Moxatag would have. Spoke with a Dr who was already familiar with Mox. His impression is that for an antibiotic that a patient only has to deal with for a week or so, noone wants to pay up for the convenience of once a day. However, he felt there are very few quality time release pill platforms on the market right now - and that for scripts that people must take over the long haul - patients would actually pay up for the convenience of once a day. Can they change their biz plan and become a partner for other drug companies with drugs that would fit the sweet spot (don't forget, big pharma loves to 'evergreen' their blockbusters as patents start to expire - new formulations work best for that). With the NOLs, the existing company would be the best place to give that a try - Grave Dancer Sam Zell has a huge piece of this - added more in Dec 09 I think it was at .40 - 2 mm more shares if memory serves bringing his total holdings to close to half of the co. If you take a close look at the liability side, most are just accounting numbers that will not represent true claims that must be paid in a bk court.
News 
Market Data 
Discover 
